Arcutis Biotherapeutics, Inc.

ARQT Healthcare Biotechnology

Arcutis Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 91.3% from fiscal 2024.

Revenue
+45.1%
EPS
+12.0%
Free cash flow
+1,171.9%
Total debt
+0.83%

Quarter to September 2026, against a year earlier

25.55 1.45 −5.37%
Market cap
$3.4B
P/E
112×
Fwd P/E
81.2×
Dividend yield
—
F-score
4/9
Altman Z
6.98
Beneish M
−1.52
Dividend safety
n/a

Arcutis Biotherapeutics, Inc. (ARQT) Net margin

Alert me on Net margin

Arcutis Biotherapeutics, Inc.'s net margin over the twelve months to 30 September 2026 was 5.88%, up 10.2 percentage points from fiscal 2025 (−4.29%). Over the past ten years it has ranged from −8,449.8% (fiscal 2022) to 0.00% (fiscal 2021); the current reading is higher than 44% of that period. That is above the Biotechnology industry median of 0.00% and above the Healthcare sector median of 0.00%.

Net margin, annual

Embed this chart

Annual newest first

Period Net margin Change (points)
FY2025 −4.29% 66.96
FY2024 −71.3% 368.54
FY2023 −439.8% 8,009.97
FY2022 −8,449.8% (8,449.76)
FY2021 0.00% 0.00
FY2020 0.00% 0.00
FY2019 0.00% 0.00
FY2018 0.00% 0.00
FY2017 0.00% —

Quarterly newest first

Period Net margin Change (points)
Sep 2026 6.12% (5.44)
Jun 2026 11.6% 22.28
Mar 2026 −10.7% (24.15)
Dec 2025 13.4% 5.96
27 more quarters

Against its own ten years

Low −8,449.8% High 0.00%
Ten-year median 0.00%
Current reading's percentile 93

Net margin against peers

What Net margin is

Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.

Net Income Allotted to Shareholders ÷ Revenue

The full definition of Net margin →

More on ARQT